Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare coverage of self-injectable products

Executive Summary

"South Carolina has the national distinction of being the only state in the U.S. where the Part B Carrier does not cover interferon for any indication...[or] the pre-operative use of epoetin alpha," Greenville, S.C. oncologist Mark O'Rourke told a recent HCFA "town hall" meeting. "The Pink Sheet" incorrectly listed products that O'Rourke considers to be "most-effectively administered by subcutaneous injection," including Amgen's Neupogen, Immunex' Leukine and Ortho's Procrit, as products not covered by the Medicare carrier (1"The Pink Sheet" July 31, p. 10)

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel